Homeopathic Periodontal Gum Relief Formula
- Manufacturer
- Indiana Botanic Gardens | ASI Marketing Group
- Effective date
- 2011-03-25
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 2
- Source
- legacy-cache
- Hydrated at
- 2026-08-02 01:51:12
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
OTC - ACTIVE INGREDIENT SECTION
I n g r e d i e n t s :
Deadly nightshade................................ 30X HPUS
Sodium borate........................................ 30X HPUS
Impure calcium sulfide............. 30X HPUS
Nitric acid......................... 30X HPUS
The letters “HPUS” indicate that the components in
this product are officially monographed in the
Homeopathic Pharmacopoeia of the United States.
OTC - PURPOSE SECTION
as an aid in reducing pain and swelling of the mouth and teeth
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
KEEP OUT OF
REACH OF CHILDREN.
INDICATIONS & USAGE SECTION
WARNINGS SECTION
Warning: If you are taking any medications or
are pregnant or breast feeding do not use prior to
consulting a physician.
DOSAGE & ADMINISTRATION SECTION
Suggested Use: Adults, take 2 tablets, dissolve under tongue or
chew 2 times daily after brushing teeth, or as directed by a health care
professional. If using toothpaste or mouthwash with mint wait 15 minutes before
taking tablets. If symptoms persist for more than 10 days consult a
health professional.
INACTIVE INGREDIENT SECTION
Inactive Ingredients: Dextrose, Magnesium
Stearate, Silica.
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
NDC# 1057804690
Homeopathic Periodontal Gum Relief Formula
as an aid in reducing pain and swelling of the mouth and teeth300 mg.
90 Tablets
USER SAFETY WARNINGS SECTION
For your protection, this container has an outer
safety seal. (Do not accept if missing or broken.)
Best if used by date on bottle. Store in a dry cool place.
Any Questions? 1-800-644-8327
website:
www.botanicchoice.com
SPL UNCLASSIFIED SECTION
FDA Establishment #: 1811575
Distributed by: Indiana Botanic Gardens, Inc.
3401 W. 37th Ave. Hobart, IN 46342
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 10578-046-90 | 2021-01-22 | C162847 | 48780-1 | 960f7f55-ce75-8e05-e053-dbdaa90a074a | Homeopathic Periodontal Gum Relief Formula |
| 10578-046-90 | 2019-10-29 | C162847 | 48780-1 | 960f7f55-ce75-8e05-e053-dbdaa90a074a | Homeopathic Periodontal Gum Relief Formula |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ATROPA BELLADONNA | ACTIVE INGREDIENT | WQZ3G9PF0H | 2 | |
| CALCIUM SULFIDE | ACTIVE INGREDIENT | 1MBW07J51Q | 2 | |
| NITRIC ACID | ACTIVE INGREDIENT | 411VRN1TV4 | 2 | |
| SODIUM BORATE | ACTIVE INGREDIENT | 91MBZ8H3QO | 2 | |
| ATROPA BELLADONNA | ACTIVE MOIETY | WQZ3G9PF0H | 2 | |
| BORATE ION | ACTIVE MOIETY | 44OAE30D22 | 2 | |
| CALCIUM CATION | ACTIVE MOIETY | 2M83C4R6ZB | 2 | |
| NITRIC ACID | ACTIVE MOIETY | 411VRN1TV4 | 2 | |
| DEXTROSE | INACTIVE INGREDIENT | IY9XDZ35W2 | 2 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 2 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 2 |
Products#
Every source-derived product name is available through these pages.
- Homeopathic Periodontal Gum Relief Formula
- Belladonna, Sodium borate, Hepar sulphuris calcareum, Nitricum acidum
- ATROPA BELLADONNA
- SODIUM BORATE
- SODIUM CATION
- BORATE ION
- CALCIUM SULFIDE
- CALCIUM CATION
- NITRIC ACID
- DEXTROSE
- MAGNESIUM STEARATE
- SILICON DIOXIDE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 10578-046 | 10578-046-90 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| ATROPA BELLADONNA | WQZ3G9PF0H | ACTIB |
| SODIUM BORATE | 91MBZ8H3QO | ACTIB |
| CALCIUM SULFIDE | 1MBW07J51Q | ACTIB |
| NITRIC ACID | 411VRN1TV4 | ACTIB |
| DEXTROSE | IY9XDZ35W2 | IACT |
| MAGNESIUM STEARATE | 70097M6I30 | IACT |
| SILICON DIOXIDE | ETJ7Z6XBU4 | IACT |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, CHEWABLE / ORAL | 254 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SUSPENSION / ORAL | 400 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / VAGINAL | 8 %w/w | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / TOPICAL | 104 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, ORALLY DISINTEGRATING / ORAL | 187 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE / ORAL | 300 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TROCHE / ORAL | 315 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / DENTAL | 19 %w/w | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, EXTENDED RELEASE / ORAL | 168 mg | ||
| DEXTROSE | DEXTROSE | IY9XDZ35W2 | LOZENGE / BUCCAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FILM COATED / ORAL | 166 mg | ||
| DEXTROSE | DEXTROSE | IY9XDZ35W2 | INJECTION, SOLUTION / INTRAVENOUS | 51.7 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED / ORAL | 3 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FOR SUSPENSION / ORAL | 220 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER, FOR SOLUTION / ORAL | 280 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | PASTE / DENTAL | 34 %w/w | ||
| DEXTROSE | DEXTROSE | IY9XDZ35W2 | SPRAY, METERED / NASAL | 50 mg | ||
| DEXTROSE | DEXTROSE | IY9XDZ35W2 | INJECTION / INTRAVENOUS | 5 %w/v | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | LOZENGE / ORAL | 420 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER, FOR SUSPENSION / ORAL | 120 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TAMPON / VAGINAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 69 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 47 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE, DELAYED RELEASE / ORAL | 1060 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE / RESPIRATORY (INHALATION) | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, DELAYED RELEASE / ORAL | 3.2 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / BUCCAL | 3 mg | ||
| DEXTROSE | DEXTROSE | IY9XDZ35W2 | POWDER / VAGINAL | 430 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / NASAL | 20 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | INSERT / VAGINAL | 8 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | DROPS / ORAL | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, CHEWABLE / ORAL | 127 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | PELLET / ORAL | 34 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER / ORAL | 602 mg | ||
| DEXTROSE | DEXTROSE | IY9XDZ35W2 | TABLET, EXTENDED RELEASE / ORAL | 103.95 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 9 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / TOPICAL | 6 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, COATED / ORAL | 184 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SUPPOSITORY / RECTAL | 14 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | DROPS / ORAL | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, SUGAR COATED / ORAL | NA | ||
| DEXTROSE | DEXTROSE | IY9XDZ35W2 | PASTILLE / ORAL | 826 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / ORAL | 750 mg | ||
| DEXTROSE | DEXTROSE | IY9XDZ35W2 | TROCHE / ORAL | 903.5 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | FILM, EXTENDED RELEASE / TRANSDERMAL | 49 mg | ||
| DEXTROSE | DEXTROSE | IY9XDZ35W2 | INJECTION / INTRAMUSCULAR | 5 %w/v | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE, EXTENDED RELEASE / ORAL | 117 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, ORALLY DISINTEGRATING / ORAL | 68 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | IMPLANT / INTRAVITREAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 2 mg | ||
| DEXTROSE | DEXTROSE | IY9XDZ35W2 | POWDER, FOR SOLUTION / ORAL | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | IMPLANT / SUBCUTANEOUS | 0.5 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, FILM COATED / ORAL | 96 mg | ||
| DEXTROSE | DEXTROSE | IY9XDZ35W2 | INJECTION, SOLUTION / INTRATHECAL | 1925 mg | ||
| DEXTROSE | DEXTROSE | IY9XDZ35W2 | SOLUTION / INTRAVENOUS | 5.05 %w/v | ||
| DEXTROSE | DEXTROSE | IY9XDZ35W2 | TABLET / SUBLINGUAL | 115.78 mg | ||
| DEXTROSE | DEXTROSE | IY9XDZ35W2 | TABLET / ORAL | 183.66 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / RESPIRATORY (INHALATION) | 0.13 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 5b43f978-d935-4790-87f0-d963459286ef | f0c0d2a3-882e-42c5-b482-464052c5ed53 | 2021-01-22 | Warnings | f0c0d2a3-882e-42c5-b482-464052c5ed53 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
